{"title":"住院抑郁症患者的临床反应、血浆水平及药代动力学","authors":"Pavel D Hrdina , Yvon D Lapierre","doi":"10.1016/0364-7722(81)90100-4","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>1.</span><span><p>1. Correlation between clinical response and plasma levels was investigated in seven patients with endogenous depression treated with 2×1 mg/kg/day of desipramine (DMI) for 21 days. Clinical response was measured by reduction in Hamilton Depression Rating Scale (HDRS) scores.</p></span></li><li><span>2.</span><span><p>2. A beneficial effect of DMI was seen in five out of seven patients studied and was fully evident already one week after the beginning of treatment.</p></span></li><li><span>3.</span><span><p>3. Great inter-individual differences were observed in DMI plasma levels both after a single dose and at ‘steady state’. The maximum plasma concentration after a single dose (C<sub>max</sub>) ranged between 19 and 179 ng/ml and the mean ‘steady state’ concentration between 65 and 240 ng/ml.</p></span></li><li><span>4.</span><span><p>4. No significant correlation was found between HDRS scores and plasma levels of DMI; however, a plot of plasma levels and amelioration scores at the end (22nd day) of treatment was suggestive of a curvilinear relationship.</p></span></li><li><span>5.</span><span><p>5. Post ‘steady state’ plasma disappearance half-lives of DMI calculation in four patients ranged from 11.5 to 34.3 hr (mean ± S.E.M. = 26.2 ± 5.0).</p></span></li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90100-4","citationCount":"14","resultStr":"{\"title\":\"Clinical response, plasma levels and pharmacokinetics of desiramine in depressed in-patients\",\"authors\":\"Pavel D Hrdina , Yvon D Lapierre\",\"doi\":\"10.1016/0364-7722(81)90100-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>1.</span><span><p>1. Correlation between clinical response and plasma levels was investigated in seven patients with endogenous depression treated with 2×1 mg/kg/day of desipramine (DMI) for 21 days. Clinical response was measured by reduction in Hamilton Depression Rating Scale (HDRS) scores.</p></span></li><li><span>2.</span><span><p>2. A beneficial effect of DMI was seen in five out of seven patients studied and was fully evident already one week after the beginning of treatment.</p></span></li><li><span>3.</span><span><p>3. Great inter-individual differences were observed in DMI plasma levels both after a single dose and at ‘steady state’. The maximum plasma concentration after a single dose (C<sub>max</sub>) ranged between 19 and 179 ng/ml and the mean ‘steady state’ concentration between 65 and 240 ng/ml.</p></span></li><li><span>4.</span><span><p>4. No significant correlation was found between HDRS scores and plasma levels of DMI; however, a plot of plasma levels and amelioration scores at the end (22nd day) of treatment was suggestive of a curvilinear relationship.</p></span></li><li><span>5.</span><span><p>5. Post ‘steady state’ plasma disappearance half-lives of DMI calculation in four patients ranged from 11.5 to 34.3 hr (mean ± S.E.M. = 26.2 ± 5.0).</p></span></li></ul></div>\",\"PeriodicalId\":20801,\"journal\":{\"name\":\"Progress in neuro-psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0364-7722(81)90100-4\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in neuro-psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0364772281901004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neuro-psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0364772281901004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical response, plasma levels and pharmacokinetics of desiramine in depressed in-patients
1.
1. Correlation between clinical response and plasma levels was investigated in seven patients with endogenous depression treated with 2×1 mg/kg/day of desipramine (DMI) for 21 days. Clinical response was measured by reduction in Hamilton Depression Rating Scale (HDRS) scores.
2.
2. A beneficial effect of DMI was seen in five out of seven patients studied and was fully evident already one week after the beginning of treatment.
3.
3. Great inter-individual differences were observed in DMI plasma levels both after a single dose and at ‘steady state’. The maximum plasma concentration after a single dose (Cmax) ranged between 19 and 179 ng/ml and the mean ‘steady state’ concentration between 65 and 240 ng/ml.
4.
4. No significant correlation was found between HDRS scores and plasma levels of DMI; however, a plot of plasma levels and amelioration scores at the end (22nd day) of treatment was suggestive of a curvilinear relationship.
5.
5. Post ‘steady state’ plasma disappearance half-lives of DMI calculation in four patients ranged from 11.5 to 34.3 hr (mean ± S.E.M. = 26.2 ± 5.0).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
